

Available online at http://www.journalcra.com

International Journal of Current Research Vol. 15, Issue, 10, pp.26306-26311, October, 2023 DOI: https://doi.org/10.24941/ijcr.45929.10.2023

INTERNATIONAL JOURNAL OF CURRENT RESEARCH

RESEARCH ARTICLE

DESIGN OF DRUG MOLECULES FOR CRI DU CHAT SYNDROME USING BIO-INFORMATIC TOOLS

¹Rabindra Kumar Mishra, ²Priyadarshini Panda and ³Ganugula Naveen Kumar

¹Department of Basic science and Humanities, GIETU, Gunupur, Odisha ^{2,3}Department of Biotechnology GIETU, Gunupur, Odisha

ARTICLE INFO

ABSTRACT

Article History: Received 25th July, 2023 Received in revised form 27th August, 2023 Accepted 15th September, 2023 Published online 31st October, 2023

Key words:

Cajanus cajan, Root, Stem, Leaves, Phytochemical Constituents, Pharmacological Effects.

*Corresponding author: *Rabindra Kumar Mishra* Our study shows that in addition to proportion and position of the 5p deletion, of the factors may alter the brain function of patients with the 5p deletion. cri du chat syndrome, or 5p deletion syndrome, is a raremedical condition that affects 1 in 50,000 newborn. Mental illness depends on the approximate proportion and position of the 5pd eletion, but in most cases the mental illness is a normal negative for the 5p deletion. He has a soft, gentle voice like a cat. One of the characteristics of new burns is a loud catchy, and this is often considered a diagnosis of illness. However, meowing behaviour observed in individuals whose deletion was limited to 5p15.3 but without the dysmorphic and growth -like condition. Although the size of the deletion varies, in anycasethemainpart deleted is 5p15.2 This paper suggests the type of chemical compound to support the behaviour of the patient includes loudcrying, psychomotor retardation, microcephaly, growth retardation, and craniofacial abnormalities including round face, protrusion, broad nasal bridge and downward-sloping palpebral fissures. We present Some clinical features such as elongated face, large stoma and scoliosis have been reported. This study provide drug, MR level, population genetic and telomere length. Diagnos is may be difficult in some patients with advanced age at first presentation. Some of these have craniofacial features similar to Angelman syndrome. Patients of ten experi encetrauma, self-harm, and violence

Copyright©2023, Rabindra Kumar Mishra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Rabindra Kumar Mishra, Priyadarshini Panda and Ganugula Naveen Kumar. 2023. "Design of drug molecules for cri du chat syndrome using bio-informatic tools". International Journal of Current Research, 15, (10), 26306-26311.

INTRODUCTION

Cri du chat syndrome is a one of the rare genetic disorder due to some errors in the chromosomes (22q11). It is named as cri du chat syndrome as it was first discovered by Jerome Jejune in 1963.So, this is also known as 5p-syndrome. He named this disorder called as cry of the cat, because the people with this disease make sound like cry of the cat. It is a hereditary congenital syndrome. (1) It affects one in 50,000 peopleacross the world. It frequently observed in female by a 4:3 ratios. After some research it is know that-this disorder caused by error occur at the end of the short (p) arm of chromosome 5 and a small section of the long arm (q) of human chromosome 22 being present 3times (trisomy) or 4times (tetratomic) instead of the usual 2times. By this deletion multiple genes are missing or deleted. This condition happens randomly during to the formation of reproductive cells in early fatal stage. most of the cri du chat disorder is not inherited. Another cause of this disorder is unbalanced translocations which further cause birth defects and other health problems. (1) The protein name telomerase reverse transcriptase (hTERT) is affected by this syndrome. Cri du Chat Syndromes (CdCs) are treatableconditions with an incidence of 1in15,000 to 1in50,000. The description of this material and its 5p deletion characteristics may help further refine the phenotype-genotype relationshipbetweenCdC and autism spectrum disorder.

SYMPTOMS

Deletions of many genes will affect the phenotype and evidence. The main symptoms of speech syndrome are:

Abnormal growing head.

- Forehead is colossal in size.
- Delay in growth of the body.
- Cardiovascular abnormalities.
- A high pitched cat like cry.
- Broad spaced eyes i.e. HYPERTELORISM.
- Abnormally shaped or ears are small in size.
- A tiny jaw i.e. MICROGNTHIA.
- Delicate muscles tonieri.e. HYPOTONIA.
- Anal atresia. (Abnormal obstruction of the anus).

Other symptoms like

- Moderate hearing.
- Cleft palate means incomplete closure of the roof of the mouth.

Nephrological problems

- Scoliosis or skeletal problems.
- Short stature.

Table 1. Molecular Drug

| SL | NAME OF | MOLECULAR | MOLECULAR | SOURCE | DRUGBANK | URL |
|-----|----------------------|---|---------------------------------|--|---------------|--|
| NO. | THE DRUGS | FORMULA | STRUCTURE | | ACESSION NO. | |
| 1 | Bitter DB 389 | | | | ChemDB7597489 | NIH Clinical Collection via Pub Chem SAM003107541 O SAM003107541 |
| 2 | Haloperidol | C ₂₁ H ₂₃ CIFNO ₂ | | Haloperidol is a phenylbutylpiper idine derivative with antipsychoti c, neuroleptic and antiemetic acti vities. It is a very potent first gene ration (regular) antipsychotic and one of the most commonly prescri bed antipsychotics worldwide. | DB00502 | https://go.drugbank.co m/drugs/DB00502 |
| 3 | Crizotinib | C ₂₁ H ₂₂ Cl ₂ FN ₅ O | | Crizotinib is an oral aminopyridin e receptor tyrosine kinase anaplas tic lymphoma kinase (ALK) and hepatocyte growth factor receptor (HGFR) inhibitor with antineopl astic activity. Binds and inhibits ALK in ATP competition kinase and ALK fusion proteins. | DB08865 | https://go.drugbank.co m/drugs/DB08865 |
| 4 | Quinidine | C ₂₀ H ₂₄ N ₂ O ₂ | | Quinidine is an alkaloid extracted from the bark of cinchona with a nti- malarial effects. It also stabilizes neuronal membranes by binding t o and inhibiting voltage- gated sodium channels. | DB00908 | https://go.drugbank.co m/drugs/DB00908 |
| 5 | Rumex crispus top | | | Rumex crispus top allergenic extract which is used in allergenic testing. | DB14167 | https://go.drugbank.co m/drugs/DB14167 |
| 6 | Durvalumab | | | Durvalumab is an anti-cancer antibody. It blocks the action of PD-L1 by which activation of the T-cell increases, enhancing detection of tumour cells. | DB11714 | https://go.drugbank.co m/drugs/DB11714 |
| 7 | Guanidine | CH ₅ N ₃ | H ^H H ^H H | Guaniidine is a uremic toxin.It is an Acetylcholine Releasing Agent. The physiologic effect of this is by means of Increased Acetylcholine Activity. | DB00536 | https://go.drugbank.co m/drugs/DB00536 |

Continue

| | L | | 1100 | | | |
|----|-------------------------------|---|---|--|---------|---|
| 8 | Human immunoglobu lin G | $\frac{C_{6332}H_{9826}N_{1692}O_{19}}{_{80}S_{42}}$ | Mª A | Human Immunoglobulin G is a p ure form of human Immunoglobu lin G and other proteins used in th e treatment of immune system dis eases and many autoimmune dise ases | DB00028 | https://go.drugbank. com/drugs/DB00028 |
| | | | VII St | | | |
| 9 | Disulfiram | C ₁₀ H ₂₀ N ₂ S ₄ | | Disulfiram is an orally bioavailable carbamoyl derivative which is used in the treatment of alcoholism,.It act as an antineoplastic agent and a ferroptosis inducer. It is an organic disulfide and an organosulfur acaricide. | DB00822 | https://go.drugbank. com/drugs/DB00822 |
| 10 | Soybean oil | C ₅₇ H ₉₈ O ₁₂ | more marked | Soybean oil is a vegetable oil and a source of polyunsaturated and s aturated fatty acids. It is used as a source of calories and essential f atty acids in patients selected for t otal parenteral nutrition (TPN) th erapy and prevention of essential fatty acid deficiency. | DB09422 | https://go.drugbank. com/drugs/DB09422 |
| 11 | Hydralazine | C ₈ H ₈ N ₄ | | Hydralazine is an oral anticonvuls ant that works by causing periphe ral vasodilation. It is a member of the phthalazines, azaarenes, orth o- fused heteroarenes and hydrazine s. | DB01275 | https://go.drugbank. com/drugs/DB01275 |
| 12 | Tolcapone | C ₁₄ H ₁₁ NO ₅ | к ко но но но но но но но но но но но но но | Tolcapone is a benzophenone derivative, a member of 2- nitrophenols and a member of catechols. It is a catechol-O- methyltransferase (COMT) inhibi tor. It is used to treat Parkinson's disease. | DB00323 | https://go.drugbank. com/drugs/DB00323 |
| 13 | Methylcellula se | $C_{20}H_{38}O_{11}$ | | Methylcellulose is a methyl ether of cellulose and has laxative pro perties. It is a polymer that has many connections between suga r molecules and is used as a stabi lizer, thickener and emulsifier in food and cosmetics | DB11228 | https://go.drugbank. com/drugs/DB11228 |
| 14 | Oxytocin | $C_{43}H_{66}N_{12}O_{12}S_2$ | fort | Oxytocin has 9 amino acids with a disulfide bond between Cys 1 and 6 residues. It is an oxytocin hormone that acts as a vasodilat or and a heterocyclic peptide. It p lays an important role in coordin ation, social cognition, and even fear control. It also plays a role i n metabolic homeostasis and card iovascular regulation | DB00107 | https://go.drugbank. com/drugs/DB00107 |
| 15 | Cyproheptadi ne | C ₂₁ H ₂₁ N | | Cyproheptadineis a H1-receptor antagonist, an antipruritic drug, an anti-allergic agent and a gastrointestinal drug. It is a 1 st generation member of piperidines and a tertiary amine. It is a combine of serotonin and histamine antagonist. | DB00434 | https://go.drugbank. com/drugs/DB00434 |
| | | | | | | Continue |

| 16 | Human interferon beta | C ₇₂ H ₁₁₅ N ₁₉ O ₂₆ | Human interferon beta is a peptid e drug. It is currently studying th e treatment of COVID- 19, the disease caused by the ne w 2019 SARS-CoV-2 virus. | DB14999 | https://go.drugbank. com/drugs/DB14999 |
|----|--------------------------------------|--|--|---------|---|
| 17 | Nutmeg | C ₃₂ H ₅₆ | Nutmeg is an extract from Nutmeg used in allergy testing. | DB10676 | https://go.drugbank. com/drugs/DB10676 |
| 18 | Proparacaine | C ₁₆ H ₂₆ N ₂ O ₃ | Proparacaine yog benzoic acid de rivative anesthetic uas inhibits v oltage- gated sodium channels . | | |
| 19 | Corifollitropi n alfa (Elonva) | Not found | It can only be used by typing. It is used together with a gonadotropi n-releasing hormone (GnRH) antagonist, which is also used in the treatment of female fe rtility. | DB09066 | https://go.drugbank. com/drugs/DB09066 |

Table 2. Score Count

| NAME OF THE DRUGS | SEQUENCE ID | | SEQUENCE ALLIGMENT SCORE | | | | | REMARK | |
|-----------------------|--------------------|--------------------|--------------------------|-------|----------------|-----------|-----------|-----------|----------|
| | 1 st ID | 2 nd ID | RMSD | TM | SEQUENCE | EQUIVALEN | REFERENCE | REFERENCE | |
| | | | | SCORE | IDENTIFICATION | T RESIDUE | COVERAGE | COVERAGE | |
| Bitter DB 389 | 4A04 | 6R2U | 4.24 | 0.14 | 6% | 51 | 28% | 19% | |
| Crizotinib | 4A04 | 3ZBF | 5.66 | 0.13 | 7% | 62 | 34% | 22% | NOT |
| | | | | | | | | | SUITABLE |
| HaloperidoL | 4A04 | 6DJZ | 4.52 | 0.23 | 4% | 71 | 39% | 33% | |
| Quinidine | 4A04 | 6LQA | 3.04 | 0.03 | 4% | 31 | 17% | 3% | |
| Rumex crispus top | 4A04 | 5V7C | 1.17 | 0.08 | 13% | 15 | 8% | 10% | |
| Durvalumab | 4A04 | 5X8M | 3.8 | 0.32 | 4% | 84 | 46% | 72% | |
| Guanidine | 4A04 | 4D50 | 1.09 | 0.05 | 0% | 16 | 9% | 6% | |
| Human immunoglobulin | 4A04 | 1LVE | 3.57 | 0.33 | 6% | 84 | 46% | 74% | |
| G | | | | | | | | | |
| Disulfiram | 4A04 | 6LS5 | 6.75 | 0.19 | 5% | 104 | 57% | 32% | |
| Soybean oil | 4A04 | 6EMM | 1.37 | 0.06 | 11% | 18 | 10% | 7% | |
| Methylcellulase | 4A04 | 1A7S | 4.75 | 0.00 | 5% | 57 | 31% | 26% | |
| Tolcapone | 4A04 | 4D7B | 4.66 | 0.17 | 3% | 37 | 20% | 32% | |
| Cyproheptadine | 4A04 | 5AYF | 4.46 | 0.12 | 2% | 38 | 21% | 16% | |
| Human interferon beta | 4A04 | 1N6U | 3.6 | 0.27 | 8% | 79 | 44% | 37% | |
| Nutmeg | 4A04 | 1BX4 | 4.76 | 0.12 | 6% | 59 | 33% | 17% | |
| Propantheline | 4A04 | 1X9Q | 3.26 | 0.27 | 4% | 80 | 44% | 35% | |
| Oxytocin | 4A04 | 6TPK | 3.23 | 0.06 | 8% | 34 | 19% | 7% | |
| Corifollitropin alfa | 4A04 | 2WKL | 6.2 | 0.11 | 2% | 77 | 43% | 16% | |

Table 3. Classification of MR

| ME LEVEL | DESCRIPTION | IO | PHENOTYPE | | | | |
|----------|-------------|-----|--|--|--|--|--|
| MELEVEL | | IQ | Child | Adult | | | |
| 0 | Normal | - | No MR | No MR | | | |
| 1 | Borderline | <70 | Normaldevelopment; Mino growth retardation occurs in the first year. | Yearsspent in standard school; Small/large need support | | | |
| 2 | Very mild | <65 | Growthisnormalin the first few years of life; Mildgrowth retardation occursat2-3 years of age. | Severalyears in the school model; theneed for reinforcement; basic reading, writing and math skills | | | |
| 3 | Mild | <50 | Asignificant delaying growthforseveralmonths; Significantgrowth retardation at 1-2 years | Understand everything, including long sentences; have very basic reading, writing and math skills | | | |
| 4 | Moderate | <35 | delayed significantgrowthfor several months; Significant growth retardation from 1 year ofage | Know almost everything; use smaller sentences and more characters | | | |
| 5 | Severe | <20 | Significantgrowth is delayed from months to a year; MR occurs before 1 year ofage | Easy-to-understand everyday sentences and words; Use2- 3word sentences and lots of characters; Walk | | | |
| 6 | Very severe | <10 | Significantgrowthhaslowedover the years; MRI apparently 6 months ago | I understood a few words; usually walk regularly if supported; no speech or just a few words | | | |
| 7 | Profound | | 5-year-old can't standonhisownfeet | Show little or no response; can sit and stand independently; rarely travel | | | |

| PATIENT | AGE(YEARS) | KARYOTYPING | TELOMERE LENGTH | HTERTmRNA INDUCTION |
|---------|------------|-----------------------------------|--|---------------------|
| 1 | 0-1 | 46,XY,del(5)(p13) | - | - |
| 2 | 1 | 46,XX,del(5)(p15.1) | 20,638 ± 6,141 (43,904 ± 546) | |
| 3 | 4 | 46,XY,del(5)(p13) | $15{,}819 \pm 1{,}206 \; (46{,}549 \pm 4{,}006)$ | .6 (3.1) |
| 4 | 8 | 46,XY,rec(5)dup(5q)inv(5)(p14q35) | $12,339 \pm 3,901 \ (36,240 \pm 2,290)$ | 1.6 (1.7) |
| 5 | 8.5 | 46,XX,del(5)(p13) | $12,684 \pm 1,886 \ (30,720 \pm 1,080)$ | 6.0 (5.4) |
| 6 | 8.8 | 46,XX,del(5)(p15.1) | $7,520 \pm 1,823\;(36,\!976 \pm 5,\!230)$ | .5 (2.1) |
| 7 | 10 | 46,XX,del(5)t(5;3)(p14;q31) | $6{,}552\pm 635\ (22{,}912\pm 3{,}030)$ | .7 (2.1) |
| 8 | 12 | 46,XY,del(5)(p14) | $13,461 \pm 3,419 \ (26,146 \pm 2,944)$ | 3.2 (6.6) |
| 9 | 14 | 46,XX,del(5)(p15.1) | 4,337 ± 864 (30,223 ± 3,254) | .9 (3.0) |
| 10 | 35 | 46,XX,del(5)(p14) | - | - |

Table 4. Cytogenetic Analysis

- Facing difficulties in swallowing and sucking.
- Low weight during birth.
- Flat nose.
- Multiple size fingers.
- Unusualface changes.
- Extra folding skin.
- Delay while talking.

The cri du chat syndrome cause due to disorder of two amino acids-HISTIDINE & TYROSINE.

Diagnose: There are normally three genetic tests use to diagnose the cri du chat syndrome. Such as

- **Karyotype:** It is a karyotype chromosomal analysis which express the child's chromosomes, by which we know that about the missing or deflectionor addition of the chromosome.
- **FISH testing:** The full form of the FISH is 'Fluorescence In Situ Hybridization'. This test looks for the specific changes of the gene on their positions in the child's cells.
- Chromosome microarray analysis: It is attest which is used to identify the extra duplicated and deleted the chromosomal segment of the person. (Table 1) It is also used to recognised the genetic irregularity and the condition of the disease.

There is no cure for Chatter syndrome. Treatments designed to support children and help them reach their potential include: Physical therapy to improve muscle weakness. speech therapy. The above chemical compounds used to prepare the drug molecules. On the basic of sequence identification score, equivalent residue, reference coverage and reference coverage drug molecules are selected (Table 2). In children, CdCs is defined by microcephaly, mental illness and disability. Psychotic symptom such as tantrums, self-harm, aggressive behaviour and feelings of abuse, hallucinations, depression, and selfhatred. (2) Mental illness depends on the approximate proportion and position of the 5p deletion, but in most cases the mental illness is a normally negative for the 5p deletion. He has a soft, gentle voice like cat. One of the characteristics of new-born is a loud cat cry, and this is often considered a diagnosis of illness. However, meowing behaviour was observed in individuals whose deletion was limited to 5p15.3 but without the dysmorphic and growth-like condition. (3) It has been shown that the ROPN1L gene is affected by fragmentation. Patients often experience trauma, self-harm, and violence. Cytogenetic analysis revealed a deletion at the end of chromosome 5p14, insistent with the cri-du-chat locus. (4,5) The prongs is for mental illness depends on the extent and location of the 5p deletion, but in many cases the mental illness is a normally poor due to the 5p deletion. All 15 patients (about two-thirds of patients with severe autism) were found to have numerical deviations in addition to the 5p deletion. (6,7) Limiting the analysis to only patients with the 5p deletion illuminates the effect of the deletion and shows that the reared 3 regions with different hysteresis, designated MR-I, MR-II, and MR-III. Subtraction includes MR-I, a 1. The 2-Mb region overlaps with the previously identified cri-du-chat core region, but excludes MR-II and MR-III, resulting in a delay. (Table 2) Deletion of MR-II, which is confined to the immediate adjacent MR-I, causes slight delay, whereas deletion confined to the more recent MR-III does not produce the phenotype.(8,9)

However, while deletions including MR-I gradually progress to MR-II and MR-III, dementia increases and becomes severe when all 3 regions are deleted.(Table 3)

Population Genetics: Meowing syndrome appears to be one of the most common human withdrawal symptoms, occurring in between 1 in 20,000 and 1 in 50,000. The frequency of people with severe intellectual disability (IQ less than 20) is about 1%. An important chromosomal region involved in cryogenic depression was identified at the corresponding 5p15.3 (D5S727 probe), while a chromosomal region involved in the main features of the condition resulted in a small region in the middle of 5p15.2 (D5S721 probe).(10,11) The size of the second region is about 2 Mb. Deletions that exclude both chromosomal regions present a wide range of clinical phenotypes, from severe mental retardation and microcephaly to clinically normal enotypes. (12,13) The breakpoint was located in the 5p15.2 regions, indicating that the other gene for the disease is adjacent to this region. cDNA was isolated from the critical cri-du-chat region by direct sequencing of a chromosome 5-specific cDNA library.

METHODS

Patients: The present study included 10 patients with ranging from 1 month to 35 years. The diagnosis of CdCS was based on clinical characteristics and cytogenetic analysis. h TERT status is +/- . The karyotyping data from all the patients are presented in Table3. The TERT gene is located on chromosome 5p (e.g., 5p15.33) and is the rate limiter of telomerase activity, which is important for maintaining telomere length and promoting cell proliferation. The study found that the TERT allele was deleted in every 10 patients with meowing syndrome they tested. (13,14,15) Five of seven patients had lower TERT mRNA. levels in proliferating lymphocytes than unaffected individuals. (Table 4) Patient lymphocytes exhibited shorter telomeres than individuals of the same age (P < 0.0001). Shortened replicative survival and increased chromosomal fusion rates were observed in cultured patient fibroblasts. Reconstitution of telomerase activity by ectopic expression of TERT extends telomere length, increases population doubling, and prevents end-to-end fusion of chromosomes. (14,15) It has been shown that haploid insufficiency of telomere maintenance in vivo may be one of the genetic factors that cause phenotypic changes in cridu-chat syndrome.

CONCLUSION

We found that three regions of chromosomes in patients had different MR levels. Deletions containing all or part of these three regions interact with other abnormalities in the genome to produce the full MR phenotype. Finally, our high-resolution data allowed us to advantage of areas associated with crying, facial expressions, and slow speech in "chats."

Conflict of interest: The authors have no conflict of interest to disclose.

ACKNOWLEDGEMENTS

We would like to show our gratitude to the Dr. N.V.J Rao, Registrar, GIET University, Gunupur, Rayagada, Odisha 765022. For sharing their pearls of wisdom with us during the course of this research.

REFERENCES

- Cerruti Mainardi, P., Perfumo, C., Cali, A., Coucourde, G., Pastore, G., Cavani, S., Zara, F., Overhauser, J., Pierluigi, M., Dagna Bricarelli, F. 2001. Clinical and molecular characterisation of 80 patients with 5p deletion: genotype-phenotype correlation. *J. Med. Genet.*, 38, 151-158, https://doi.org/10.1136/jmg.38.3.151.
- Choong, Y. F., Watts, P., Little, E., Beck, L. Goldenhar and cridu-chat syndromes: a contiguous gene deletion syndrome. J. AAPOS2003, 7, 226, https://doi.org/10.1007/s10689-017-0006-x
- Elmakky, A., Carli, D., Lugli, L., Torelli, P., Guidi, B., Falcinelli, C., Fini, S., Ferrari, F., Percesepe, A. 2014. A three-generation family with terminal microdeletion involving 5p15.33-32 due to a whole-arm 5;15 chromosomal translocation with a steady phenotype of atypical cri du chat syndrome. *Europ. J. Med. Genet.*, 57, 145-150, https://doi.org/10.1016/j.ejmg.2014.02.00
- Fang, J.-S., Lee, K.-F., Huang, C.-T., Syu, C.-L., Yang, K.-J., Wang, L.-H., Liao, D.-L., Chen, C.-H. Cytogenetic and molecular characterization of a three-generation family with chromosome 5p terminal deletion Clin. Genet. 2008, 73, 585-590, https://doi.org/10.1111/j.1399-0004.2008.00995.x
- Medina, M., Marinescu, R. C., Overhauser, J., Kosik, K. S. 2000. Hemizygosity of delta-catenin (CTNND2) is associated with severe mental retardation in cri-du-chat syndrome. Genomics, 63, 157-164, https://doi.org/10.1006/geno.1999.6090
- Nguyen, J. M., Qualmann, K. J., Okashah, R., Reilly, A., Alexeyev, M. F., Campbell, D. J. 2015. 5p deletions: current knowledge and future directions. *Am. J. Med. Genet.*, 169, 224-238, https://doi.org/10.1002/ajmg.c.31444
- Perfumo, C., Cerruti Mainardi, P., Cali, A., Coucourde, G., Zara, F., Cavani, S., Overhauser, J., Dagna Bricarelli, F., Pierluigi, M. 2000. The first three mosaic cri du chat syndrome patients with two rearranged cell lines., *J. Med. Genet.*, 37, 967-972, https://doi.org/10.1136/jmg.37.12.967

- South, S. T., Swensen, J. J., Maxwell, T., Rope, A., Brothman, A. R., Chen, Z. A new genomic mechanism leading to cri-du-chat syndrome. Am. J. Med. Genet. 2006, 140, 2714-2720, https://doi.org/10.1002/ajmg.a.31496.
- Van Buggenhout, G. J. C. M., Pijkels, E., Holvoet, M., Schaap, C., Hamel, B. C. J., Fryns, J. P. Cri du chat syndrome: changing phenotype in older patients. Am. J. Med. Genet. 2000, 90, 203-215, https://doi.org/10.1002/(SICI)1096-8628(20000131)90:3<203::AID-AJMG5>3.0.CO;2-A
- Zhang, A., Zheng, C., Hou, M., Lindvall, C., Li, K.-J., Erlandsson, F., Bjorkholm, M., Gruber, A., Blennow, E., Xu, D. Deletion of the telomerase reverse transcriptase gene and haploinsufficiency of telomere maintenance in cri du chat syndrome. Am. J. Hum. Genet. 2003, 72: 940-948, https://doi.org/10.1086/374565
- Zhang, X., Snijders, A., Segraves, R., Zhang, X., Niebuhr, A., Albertson, D., Yang, H., Gray, J., Niebuhr, E., Bolund, L., Pinkel, D. 2005. High-resolution mapping of genotype-phenotype relationships in cri du chat syndrome using array comparative genomic hybridization., *Am. J. Hum. Genet.*, 76: 312-326., https://doi.org/10.1086/427762.
- Wilkins LE, Brown JA, Nance WE. 1983. Wolf B Clinical heterogeneity in 80 home-reared children with cri du chat syndrome. J Pediatr, 102:528–533, https://doi.org/ 10.1016/ S0022-3476 (83)80179-6
- Saretzki G, Petersen S, Petersen I, Ko" lble K, von Zglinicki T hTERT gene dosage correlates with telomerase activity in human lung cancer cell lines. Cancer Lett 2002 176:81–91, https://doi.org/10.1016/S0304-3835(01)00644-9.
- Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albertson DG, Pinkel D. 2002. Fully automatic quantification of microarray image data. *Genome Res.*, 12:325–332, https://doi.org/10.1101/gr.210902
- Eichler EE. 2001. Recent duplication, domain accretion and the dynamic mutation of the human genome. Trends Genet, 17: 661– 669, https://doi.org/10.1016/s0168-9525(01)02492-1.
